Genome-guided prioritization of rifabutin MIC testing among rifampicin high-MIC Mycobacterium tuberculosis isolates: a retrospective development and internal evaluation study

Read the full article

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background Quantitative rifabutin testing can resolve rifamycin cross-resistance patterns, but testing capacity is limited. We evaluated whether whole-genome mutation profiles could concentrate rifabutin low-MIC isolates into a small, high-yield confirmatory-testing worklist among rifampicin high-MIC Mycobacterium tuberculosis isolates. Methods This retrospective development and internal evaluation study used paired whole-genome and broth-microdilution data from the CRyPTIC consortium. The research endpoint was rifabutin MIC ≤ 0.12 mg/L among isolates with rifampicin MIC > 0.5 mg/L. Subject-grouped nested cross-validation included fold-specific model selection and fold-local ranking at testing budgets of 5%, 10%, 15%, and 20%. A compact rpoB logistic procedure was compared with broader learned models and rule-based genomic comparators. Results Among 3,466 eligible isolates from 3,397 subjects, 210 (6.1%) met the rifabutin low-MIC endpoint. Testing the highest-ranked 10% selected 348 isolates and recovered an expected 151.0 of 210 low-MIC events (71.9%; 95% subject-cluster confidence interval, 65.2–77.4%), increasing worklist yield to 43.4%. A cross-validated carrier ≥ 10 rpoB logistic procedure recovered 71.5% (64.9–76.7%) and had an area under the precision–recall curve of 0.425, compared with 0.438 for the nested procedure. Collection-site and phylogenetic-lineage holdouts showed heterogeneous performance. The compact procedure was separately refitted on the full cohort as a frozen 37-feature candidate. Conclusions Genome-guided ranking substantially enriched a limited rifabutin MIC testing worklist among rifampicin high-MIC isolates. The compact rpoB procedure provides a transparent candidate for independent prospective evaluation in specialist clinical microbiology laboratories while retaining phenotypic MIC testing as the confirmatory measurement.

Article activity feed